Category: Antibody-drug conjugate
Accelerating a Global, FIH ADC Therapy Trial for Lung Cancer An innovative biotech was developing a next-generation antibody-drug conjugate (ADC) for the treatment of non-small Read Now 
Reflections from ESMO 2025 Progress, Breakthrough Science and the Future of Oncology We were delighted to attend the recent Read Now 
Key Takeaways from ADCs in Oncology Trials Webinar This executive summary captures the key takeaways from a webinar I moderated titled “ADCs in Read Now 
ADCs in Oncology Trials Webinar Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment and heralding in a new era of targeted Read Now 
The Resurgence of Antibody-drug Conjugates How ADCs are redefining cancer therapy Cancer treatment is undergoing a transformation, fueled by advances Read Now 
Precision Medicine The Rise of Targeted Cancer Therapies New cancer cases are expected to increase globally from Read Now 
Highlights of ASCO 2025 Translating research into real-world results for cancer patients I joined over 45,000 oncology professionals at McCormick Read Now 
Key Takeaways from World ADC 2024 The resurgence of ADCs in cancer therapy The World ADC conference is the leading conference Read Now 
Highlights of ESMO 2024 Recent Advances in Oncology Drug Development I was honored, along with my Catalyst Oncology colleagues, Read Now 
Highlights of ASCO 2024 Cancer Drug Development and Trends It is hard to imagine that it has only been Read Now